Pediatric Liver Fat Quantification (LFQ) Phase 2 Pilot Study

Sponsor

Philips Clinical & Medical Affairs Global (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04800094

Collaborator

(none)

Enrollment

Location

Arm

17.9

Anticipated Duration (Months)

1.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This clinical study will involve performing a series of medical imaging procedures of the abdomen using both ultrasound and MRI modalities in subjects at risk for or already diagnosed with Nonalcoholic Fatty Liver Disease (NAFLD). The primary objective of this clinical study is to evaluate the clinical feasibility of an investigational ultrasound technique for quantifying liver fat by comparing specific ultrasound-derived biomarkers with the liver fat percentage obtained from MRI Proton Density Fat Fraction (MRI-PDFF) measurements. All subjects enrolled in this study will undergo one investigational abdominal ultrasound examination using the Philips EPIQ Ultrasound System and one MRI PDFF examination according to the clinical standard of care.

Condition or Disease	Intervention/Treatment	Phase
Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis	Device: Investigational Liver Fat Quantification Software	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Pilot Study of On-Cart Liver Fat Quantification (LFQ) Feature to Assess Correlation With Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) Results in a Pediatric Population

Actual Study Start Date :

Mar 2, 2021

Anticipated Primary Completion Date :

Aug 30, 2022

Anticipated Study Completion Date :

Aug 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Investigational Ultrasound Imaging for Liver Fat Quantification	Device: Investigational Liver Fat Quantification Software All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.

Arm

Intervention/Treatment

Experimental: Investigational Ultrasound Imaging for Liver Fat Quantification

Device: Investigational Liver Fat Quantification Software

All subjects enrolled in this study will undergo two abdominal ultrasound examinations using the investigational Liver Fat Quantification feature on the Philips EPIQ Ultrasound System. In addition, all subjects will also undergo one MRI-PDFF examination according to the clinical standard of care.

Outcome Measures

Primary Outcome Measures

Correlation of the liver fat percentage reported from MRI-PDFF with measurements of ultrasound biomarkers for liver fat. [Intra-procedural (1 day)]
Correlation of each ultrasound biomarker with the liver fat percentage reported from MRI-PDFF will be assessed independently to evaluate individual biomarker performance.

Secondary Outcome Measures

Inter-operator variability in measurements of ultrasound biomarkers for liver fat [Intra-procedural (1 day)]
Inter-operator variability will be assessed by comparing the ultrasound biomarkers measured from each subject by two different operators who have received standardized training. Following biomarkers will be measured: Hepatorenal Index Acoustic attenuation
Ultrasound biomarker measurement failure rate [Intra-procedural (1 day)]
The ultrasound biomarker measurement failure rate will be assessed by measuring the percentage of subjects in whom measurements cannot be made due to technical limitations.

Eligibility Criteria

Criteria

Ages Eligible for Study:

5 Years to 21 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subjects at least 5 years old up through and including 21 years old who are able to provide informed consent to participate or have a legal representative/parent/legal guardian who is able to provide informed consent for the subject to participate.
Subjects must be eligible for a standard abdominal ultrasound examination and standard non-contrast MRI examination.

In addition, at least one of the following criteria must also be met:

Overweight or obese (BMI-for-age ≥ 85th percentile).
Diagnosed with Type 2 diabetes per standard clinical guidelines.
Diagnosed with hypercholesterolemia per standard clinical guidelines.
Diagnosed with or clinically suspected of having NAFLD/NASH based on previous medical record, medical imaging, liver biopsy, and/or laboratory testing.

Exclusion Criteria:

History of moderate/heavy/binge alcohol consumption exceeding NIAAA guidelines.
Evidence of hepatotoxicity or cirrhosis in the clinical judgment of the investigator.
History of chronic liver disease other than NAFLD (e.g., viral, cholestatic, or autoimmune).
Use of drugs associated with hepatic steatosis:
Amiodarone
Methotrexate
Nucleoside reverse transcriptase inhibitors (didanosine, stavudine)
Valproic acid
Dexamethasone
Tamoxifen
5-FU-based adjuvant chemotherapy
Apo-B inhibitors (mipomersen, lomitapide)
Tetracycline exceeding 2 g/day
Acetylsalicylic acid exceeding 150 mg/kg